Antibody titers and immune response to diphtheria-tetanus-pertussis and measles-mumps-rubella vaccination in children treated for acute lymphoblastic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 27, Issue 5, 2005, Pages 273-277

  Ercan, Tugba Erener ^a   Soycan, Lebriz Yüksel ^a   Apak, Hilmi ^a   Celkan, Tiraje ^a   Ozkan, Alp ^a   Akdenizli, Emine ^b   Kasapçopur, Ozgur ^a   Yildiz, Inci ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Acute lymphoblastic leukemia; Antibody response; Immunization

Indexed keywords

ACELLULAR VACCINE; ANTIBODY; ANTINEOPLASTIC AGENT; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; TETANUS ANTIBODY; TETANUS TOXOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARM SWELLING; ARTICLE; BRAIN RADIATION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE STATUS; IMMUNIZATION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; STATISTICAL ANALYSIS;

ADOLESCENT; ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION; LEUKEMIA, LYMPHOCYTIC, ACUTE; MEASLES VACCINE; REFERENCE VALUES; RUBELLA VACCINE;

EID: 18944363239     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000163214.37147.5a     Document Type: Article

References (29)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia: current status and future perspectives. Lancet Oncol. 2001; 2:597-607.
2. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992;69:1481-1486.
3. Smith S, Schiffman G, Karayalcin G, et al. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt- Münster therapy. J Pediatr. 1995;127:68-75.
4. Ridgway D, Wolff LJ, Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child. 1991; 145:887-891.
5. Parkkali T, Ruutu T, Stenvik M. Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogenic bone marrow transplantation. APMIS. 1996;104:383-388.
6. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V, et al. Long-term immunity to measles, rubella and mumps in patients after allogeneic bone marrow transplantation. Blood. 1994;84:657-663.
7. Hammarstrom V, Pauksen K, Bjorkstrand B, et al. Tetanus immunity in autologous bone marrow and blood stem transplantation recipients. Bone Marrow Transplant. 1998;22:67-71.
8. Ljungman P, Cordonnier C, de Bock R, et al. Immunizations after bone marrow transplantation: results of a European survey and recommendations from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995; 15:445-460.
9. Parkkali T, Olenter RM, Ruutu T, et al. A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant. 1997;19:933-938.
10. Henning KJ, White MH, Sepkowitz KA, et al. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA. 1997;277:1148-1151.
11. Ljungman P. Immunization of transplant recipients. Bone Marrow Transplant. 1999;23:637-646.
12. Avigan D, Pirofski LA, Lazarus HM. Vaccination against infectious disease following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:171-183.
13. van der Does-van den Berg A, Hermans J, Nagel J, et al. Immunity to diphtheria, pertussis, tetanus and poliomyelitis in children with acute lymphoblastic leukemia after cessation of chemotherapy. Pediatrics. 1981;67:222-229.
14. Kung FH, Orgel HA, Wallace WW, et al. Antibody production following immunization with diphtheria and tetanus toxoids in children receiving chemotherapy during remission of malignant disease. Pediatrics. 1984;74: 86-89.
15. Nyerges G, Zimonyi I, Meszner Z, et al. Efficiency of tetanus toxoid booster in leukemic children. Acta Paediatr Acad Sci Hung. 1981;67: 222-229.
16. Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002;109:e91.
17. Reinhardt D, Houliara K, Pekrun A, et al. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis. 2003;35:851-857.
18. Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Cancer. 2004;101:635-641.
19. Schrappe M. Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
20. Langermann HJ, Henze G, Wulf M, et al. Abschatzung der Tumorzellmasse bei der akuten lymphoblastischen Leukemie im Kindesalter: prognostische Bedeutung und praktische Anwendung. Klin Padiatr. 1982; 194:209-213.
21. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20:63-75.
22. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J. 1997;16:90-96.
23. Mustafa MM, Buchanan GR, Winick NJ, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol. 1998;20:451-457.
24. de Vaan GAM, van Munster PJJ, Bakkeren JAJM. Recovery of immune function after cessation of maintenance therapy in acute lymphoblastic leukemia of childhood. Eur J Pediatr. 1982;132:113-117.
25. Feldman S, Andrew M, Norris M, et al. Decline in rates of seropositivity for measles, mumps and rubella antibodies among previously immunized children treated for acute leukemia. Clin Inject Dis. 1998; 27:388-390.
26. Feldman S, Gigliotti F, Bockhold C, et al. Measles and rubella antibody status in previously vaccinated children with cancer. Med Pediatr Oncol. 1988;16:308-311.
27. Yeager AS, Davis JH, Ross LA, et al. Measles immunization: successes and failures. JAMA. 1977;237:347-351.
28. Kantar M, Çetingül N, Kansoy S, et al. Immune deficiencies following cancer treatment in children. J Trop Pediatr. 2003;49:286-290.
29. Brunell PA, Weigle K, Murphy MD, et al. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA. 1983;250:1409.